RxDoctor Payments Data

Ben Rad, MD

Internal Medicine · Fresno, CANPI 1063504249

Payments from drug & device makers

$3,405in general payments, 2019–2025

Across 77 payments — averaging $44.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$471
  • Novo Nordisk$470
  • Amgen$386
  • AstraZeneca$315
  • AbbVie$312
  • Abbott$220
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,405 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$34,077
Medicare patients
73
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate58$40,351
OzempicSemaglutide26$32,435
JardianceEmpagliflozin31$27,092
RybelsusSemaglutide18$24,717
EliquisApixaban26$18,181
KerendiaFinerenone21$15,217
LinzessLinaclotide15$11,637
TradjentaLinagliptin14$7,886
VascepaIcosapent Ethyl11$2,989
Metoprolol Succinate150$2,626
Atorvastatin Calcium293$2,573
Albuterol Sulfate HfaAlbuterol Sulfate52$1,724
Metformin Hcl197$1,545
Levothyroxine Sodium94$1,522
Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl11$1,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$470$57,15344 claims
MerckJanuvia$68$40,35158 claims
Boehringer IngelheimJardiance, Tradjenta$100$34,97945 claims
BayerKerendia$150$15,21721 claims
AbbVieLinzess$312$11,63715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →